NewEdge Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$387K Buy
23,788
+3,562
+18% +$59.5K ﹤0.01% 2168
2025
Q4
$339K Sell
20,226
-6,656
-25% -$112K ﹤0.01% 2225
2025
Q3
$417K Sell
26,882
-7,308
-21% -$100K ﹤0.01% 1946
2025
Q2
$438K Buy
34,190
+1,690
+5% +$20.8K ﹤0.01% 1773
2025
Q1
$412K Buy
32,500
+9,785
+43% +$133K ﹤0.01% 1694
2024
Q4
$298K Sell
22,715
-1,201
-5% -$17.3K ﹤0.01% 1884
2024
Q3
$361K Sell
23,916
-3,827
-14% -$57.9K ﹤0.01% 1677
2024
Q2
$393K Buy
27,743
+2,779
+11% +$37.6K ﹤0.01% 1556
2024
Q1
$340K Buy
24,964
+2,463
+11% +$34.1K ﹤0.01% 1572
2023
Q4
$314K Sell
22,501
-3,407
-13% -$41.9K ﹤0.01% 1531
2023
Q3
$323K Sell
25,908
-4,994
-16% -$65.7K ﹤0.01% 1388
2023
Q2
$418K Buy
30,902
+1,817
+6% +$25.1K ﹤0.01% 1276
2023
Q1
$401K Buy
29,085
+861
+3% +$12.3K 0.01% 1208
2022
Q4
$378K Buy
28,224
+130
+0.5% +$1.88K 0.01% 902
2022
Q3
$384K Buy
28,094
+1,564
+6% +$23.4K 0.01% 1085
2022
Q2
$378K Buy
26,530
+2,431
+10% +$36.7K 0.01% 1102
2022
Q1
$398K Buy
24,099
+9,500
+65% +$164K 0.01% 901
2021
Q4
$281K Buy
+14,599
New +$294K ﹤0.01% 1360

Other funds holding HQL

NewEdge Advisors's HQL Position: Q1 2026 in Review

NewEdge Advisors increased its abrdn Life Sciences Investors (HQL) stake by 18% in Q1 2026, buying an estimated $59.5K and bringing the position to 23,788 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #2168.

NewEdge Advisors first reported a position in HQL in Q4 2021 and has held it in 18 quarters since. The position peaked at $438K in Q2 2025. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • NewEdge Advisors held 23,788 shares of abrdn Life Sciences Investors worth $387K as of Q1 2026.
  • NewEdge Advisors bought 3,562 abrdn Life Sciences Investors shares in Q1 2026, an estimated $59.5K.
  • abrdn Life Sciences Investors made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2168 holding.
  • NewEdge Advisors first reported a position in abrdn Life Sciences Investors in Q4 2021 and has held it in 18 quarters since.
  • NewEdge Advisors's abrdn Life Sciences Investors position peaked at $438K in Q2 2025.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.